A detailed history of Northeast Financial Consultants Inc transactions in Fibrogen Inc stock. As of the latest transaction made, Northeast Financial Consultants Inc holds 54,699 shares of FGEN stock, worth $19,144. This represents 0.0% of its overall portfolio holdings.

Number of Shares
54,699
Previous 54,699 -0.0%
Holding current value
$19,144
Previous $48,000 56.25%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$0.89 - $2.36 $48,682 - $129,089
54,699 New
54,699 $48,000
Q2 2022

Aug 12, 2022

SELL
$7.94 - $12.96 $434,310 - $708,899
-54,699 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$12.02 - $16.79 $657,481 - $918,396
54,699 New
54,699 $657,000
Q4 2019

Feb 14, 2020

SELL
$34.58 - $48.06 $347,874 - $483,483
-10,060 Closed
0 $0
Q3 2019

Nov 13, 2019

BUY
$36.98 - $48.45 $372,018 - $487,407
10,060 New
10,060 $372,000

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $32.8M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Northeast Financial Consultants Inc Portfolio

Follow Northeast Financial Consultants Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northeast Financial Consultants Inc, based on Form 13F filings with the SEC.

News

Stay updated on Northeast Financial Consultants Inc with notifications on news.